Valuation: Opus Genetics, Inc.

Market Cap 381M 339M 316M 288M 543M 36.63B 548M 3.82B 1.48B 18.73B 1.43B 1.4B 60.1B P/E 2026 *
-4.67x
P/E 2027 * -6.47x
Enterprise Value 381M 339M 316M 288M 543M 36.63B 548M 3.82B 1.48B 18.73B 1.43B 1.4B 60.1B EV / Sales 2026 *
29.1x
EV / Sales 2027 * 28x
Free-Float
87.77%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day+1.55%
1 week-3.78%
Current month-5.37%
1 month+2.92%
3 months+8.27%
6 months+0.66%
Current year+127.86%
1 week 4.44
Extreme 4.445
5.32
1 month 4.3
Extreme 4.305
7.07
Current year 1.88
Extreme 1.88
7.07
1 year 1.7
Extreme 1.7
7.07
3 years 0.65
Extreme 0.65
7.07
5 years 0.65
Extreme 0.65
7.07
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 2023-10-31
Director of Finance/CFO 52 2025-09-01
President 60 2024-10-21
Director TitleAgeSince
Director/Board Member 77 2020-10-31
Chairman 56 2019-11-30
Director/Board Member 59 2020-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 Exercice

Chief Executive Officer

859,855 1.0335%
9/8/26 Exercice

Chairman

1,568,628 1.8855%
9/3/26 Sell

Chief Financial Officer

-28,000 0.0337%
Change 5-day change 1-year change 3-year change Capi.($)
+1.55%-3.78%+154.44%+25.82% 381M
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.06%-3.43%+39.90%+54.02% 369.76B
Weighted average by Cap. +0.42%-3.33%+30.53%+68.95%

Financials

2026 *2027 *
Net sales 13.11M 11.65M 10.87M 9.91M 18.69M 1.26B 18.86M 132M 50.99M 644M 49.23M 48.16M 2.07B 13.59M 12.08M 11.27M 10.27M 19.38M 1.31B 19.56M 136M 52.86M 668M 51.04M 49.93M 2.14B
Net income -91.93M -81.68M -76.23M -69.48M -131M -8.84B -132M -923M -357M -4.52B -345M -338M -14.5B -68.94M -61.26M -57.17M -52.11M -98.28M -6.63B -99.2M -692M -268M -3.39B -259M -253M -10.87B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
26-10-02 US$4.580 +1.55% 1,791,267
26-10-01 US$4.510 -6.82% 1,873,945
26-09-30 US$4.840 -2.32% 2,458,482
26-09-29 US$4.955 -1.88% 1,525,569
26-09-28 US$5.050 +6.09% 1,162,236
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
4.580USD
Average target price
13.00USD
Spread / Average Target
+183.84%

Quarterly revenue - Rate of surprise